000			02059 a2200589 4500
005			20250517064415.0
264		0	_c20160629
008			201606s 0 0 eng d
022			_a1528-0020
024	7		_a10.1182/blood-2015-08-660977 _2doi
040			_aNLM _beng _cNLM
100	1		_aDeininger, Michael W
245	0	0	_aCompound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. _h[electronic resource]
260			_bBlood _cFeb 2016
300			_a703-12 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAmino Acid Substitution
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aDNA Mutational Analysis _xmethods
650	0	4	_aDrug Resistance, Neoplasm _xgenetics
650	0	4	_aFusion Proteins, bcr-abl _xgenetics
650	0	4	_aHigh-Throughput Nucleotide Sequencing
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy
650	0	4	_aMutation _xphysiology
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aPyridazines _xtherapeutic use
700	1		_aHodgson, J Graeme
700	1		_aShah, Neil P
700	1		_aCortes, Jorge E
700	1		_aKim, Dong-Wook
700	1		_aNicolini, Franck E
700	1		_aTalpaz, Moshe
700	1		_aBaccarani, Michele
700	1		_aMüller, Martin C
700	1		_aLi, Jin
700	1		_aParker, Wendy T
700	1		_aLustgarten, Stephanie
700	1		_aClackson, Tim
700	1		_aHaluska, Frank G
700	1		_aGuilhot, Francois
700	1		_aKantarjian, Hagop M
700	1		_aSoverini, Simona
700	1		_aHochhaus, Andreas
700	1		_aHughes, Timothy P
700	1		_aRivera, Victor M
700	1		_aBranford, Susan
773	0		_tBlood _gvol. 127 _gno. 6 _gp. 703-12
856	4	0	_uhttps://doi.org/10.1182/blood-2015-08-660977 _zAvailable from publisher's website
999			_c25482524 _d25482524